Which has better earnings & valuation, STIM or CBLL?

Neuronetics has higher revenue and earnings than CeriBell. CeriBell is trading at a lower price-to-earnings ratio than Neuronetics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Neuronetics $149.16M 1.69 -$39M -$0.54 N/A CeriBell $89.06M 10.05 -$53.41M -$1.76 N/A

Is STIM or CBLL more profitable?

Neuronetics has a net margin of -19.62% compared to CeriBell's net margin of -64.73%. CeriBell's return on equity of -44.85% beat Neuronetics' return on equity. Company Net Margins Return on Equity Return on Assets Neuronetics -19.62% -125.11% -22.15% CeriBell -64.73% -44.85% -35.69%

Does the media favor STIM or CBLL?

In the previous week, CeriBell had 4 more articles in the media than Neuronetics. MarketBeat recorded 19 mentions for CeriBell and 15 mentions for Neuronetics. Neuronetics' average media sentiment score of 0.61 beat CeriBell's score of 0.32 indicating that Neuronetics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neuronetics 3 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive CeriBell 6 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media favor STIM or AVR?

In the previous week, Anteris Technologies Global had 7 more articles in the media than Neuronetics. MarketBeat recorded 22 mentions for Anteris Technologies Global and 15 mentions for Neuronetics. Neuronetics' average media sentiment score of 0.61 beat Anteris Technologies Global's score of 0.22 indicating that Neuronetics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neuronetics 3 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Anteris Technologies Global 8 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 3 Negative mention(s) 2 Very Negative mention(s) Neutral

Which has higher earnings & valuation, INMD or STIM?

InMode has higher revenue and earnings than Neuronetics. Neuronetics is trading at a lower price-to-earnings ratio than InMode, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio InMode $370.49M 2.35 $93.83M $1.23 12.32 Neuronetics $149.16M 1.69 -$39M -$0.54 N/A

Is INMD or STIM more profitable?

InMode has a net margin of 20.69% compared to Neuronetics' net margin of -19.62%. InMode's return on equity of 11.99% beat Neuronetics' return on equity. Company Net Margins Return on Equity Return on Assets InMode 20.69% 11.99% 10.60% Neuronetics -19.62% -125.11% -22.15%

Does the media prefer INMD or STIM?

In the previous week, Neuronetics had 12 more articles in the media than InMode. MarketBeat recorded 15 mentions for Neuronetics and 3 mentions for InMode. InMode's average media sentiment score of 0.96 beat Neuronetics' score of 0.61 indicating that InMode is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment InMode 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Neuronetics 3 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Which has preferable valuation & earnings, STIM or SIBN?

SiBone has higher revenue and earnings than Neuronetics. SiBone is trading at a lower price-to-earnings ratio than Neuronetics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Neuronetics $149.16M 1.69 -$39M -$0.54 N/A SiBone $200.93M 4.18 -$18.90M -$0.34 N/A

Is STIM or SIBN more profitable?

SiBone has a net margin of -6.85% compared to Neuronetics' net margin of -19.62%. SiBone's return on equity of -8.23% beat Neuronetics' return on equity. Company Net Margins Return on Equity Return on Assets Neuronetics -19.62% -125.11% -22.15% SiBone -6.85% -8.23% -6.07%

Does the media prefer STIM or SIBN?

In the previous week, Neuronetics had 11 more articles in the media than SiBone. MarketBeat recorded 15 mentions for Neuronetics and 4 mentions for SiBone. SiBone's average media sentiment score of 1.33 beat Neuronetics' score of 0.61 indicating that SiBone is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neuronetics 3 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive SiBone 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is BBNX or STIM more profitable?

Neuronetics has a net margin of -19.62% compared to Beta Bionics' net margin of -61.31%. Beta Bionics' return on equity of -26.30% beat Neuronetics' return on equity. Company Net Margins Return on Equity Return on Assets Beta Bionics -61.31% -26.30% -23.25% Neuronetics -19.62% -125.11% -22.15%

Does the media refer more to BBNX or STIM?

In the previous week, Neuronetics had 13 more articles in the media than Beta Bionics. MarketBeat recorded 15 mentions for Neuronetics and 2 mentions for Beta Bionics. Beta Bionics' average media sentiment score of 0.99 beat Neuronetics' score of 0.61 indicating that Beta Bionics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Beta Bionics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Neuronetics 3 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Neuronetics (STIM) Competitors

$3.30 +0.27 (+8.91%)

Closing price 04:00 PM Eastern

Extended Trading

$3.26 -0.04 (-1.24%)

As of 07:58 PM Eastern

Compare

STIM vs. CBLL, AVR, INMD, SIBN, and BBNX

Should you buy Neuronetics stock or one of its competitors? Neuronetics's main competitors and comparable companies include CeriBell (CBLL), Anteris Technologies Global (AVR), InMode (INMD), SiBone (SIBN), and Beta Bionics (BBNX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Neuronetics compare to CeriBell?

Neuronetics (NASDAQ:STIM) and CeriBell (NASDAQ:CBLL) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, earnings, dividends, risk, analyst recommendations and institutional ownership.

Neuronetics has a net margin of -19.62% compared to CeriBell's net margin of -64.73%. CeriBell's return on equity of -44.85% beat Neuronetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neuronetics	-19.62%	-125.11%	-22.15%
CeriBell	-64.73%	-44.85%	-35.69%

Neuronetics presently has a consensus target price of $4.50, indicating a potential upside of 36.36%. CeriBell has a consensus target price of $22.00, indicating a potential downside of 5.70%. Given Neuronetics' higher possible upside, research analysts clearly believe Neuronetics is more favorable than CeriBell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neuronetics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
CeriBell	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

In the previous week, CeriBell had 4 more articles in the media than Neuronetics. MarketBeat recorded 19 mentions for CeriBell and 15 mentions for Neuronetics. Neuronetics' average media sentiment score of 0.61 beat CeriBell's score of 0.32 indicating that Neuronetics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neuronetics	3 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
CeriBell	6 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

53.6% of Neuronetics shares are held by institutional investors. 8.4% of Neuronetics shares are held by insiders. Comparatively, 17.7% of CeriBell shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Neuronetics has a beta of 1.03, suggesting that its stock price is 3% more volatile than the broader market. Comparatively, CeriBell has a beta of 0.81, suggesting that its stock price is 19% less volatile than the broader market.

Neuronetics has higher revenue and earnings than CeriBell. CeriBell is trading at a lower price-to-earnings ratio than Neuronetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neuronetics	$149.16M	1.69	-$39M	-$0.54	N/A
CeriBell	$89.06M	10.05	-$53.41M	-$1.76	N/A

Summary

Neuronetics beats CeriBell on 10 of the 17 factors compared between the two stocks.

How does Neuronetics compare to Anteris Technologies Global?

Neuronetics (NASDAQ:STIM) and Anteris Technologies Global (NASDAQ:AVR) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, earnings, media sentiment, profitability, valuation and dividends.

Neuronetics has a net margin of -19.62% compared to Anteris Technologies Global's net margin of -4,619.27%. Anteris Technologies Global's return on equity of -77.69% beat Neuronetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neuronetics	-19.62%	-125.11%	-22.15%
Anteris Technologies Global	-4,619.27%	-77.69%	-67.99%

53.6% of Neuronetics shares are owned by institutional investors. 8.4% of Neuronetics shares are owned by company insiders. Comparatively, 4.5% of Anteris Technologies Global shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Neuronetics has a beta of 1.03, suggesting that its share price is 3% more volatile than the broader market. Comparatively, Anteris Technologies Global has a beta of 1.78, suggesting that its share price is 78% more volatile than the broader market.

Neuronetics has higher revenue and earnings than Anteris Technologies Global. Neuronetics is trading at a lower price-to-earnings ratio than Anteris Technologies Global, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neuronetics	$149.16M	1.69	-$39M	-$0.54	N/A
Anteris Technologies Global	$1.91M	479.65	-$94.14M	-$1.95	N/A

In the previous week, Anteris Technologies Global had 7 more articles in the media than Neuronetics. MarketBeat recorded 22 mentions for Anteris Technologies Global and 15 mentions for Neuronetics. Neuronetics' average media sentiment score of 0.61 beat Anteris Technologies Global's score of 0.22 indicating that Neuronetics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neuronetics	3 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Anteris Technologies Global	8 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	3 Negative mention(s)	2 Very Negative mention(s)	Neutral

Neuronetics currently has a consensus target price of $4.50, suggesting a potential upside of 36.36%. Anteris Technologies Global has a consensus target price of $16.00, suggesting a potential upside of 70.21%. Given Anteris Technologies Global's stronger consensus rating and higher possible upside, analysts clearly believe Anteris Technologies Global is more favorable than Neuronetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neuronetics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Anteris Technologies Global	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Summary

Neuronetics and Anteris Technologies Global tied by winning 8 of the 16 factors compared between the two stocks.

How does Neuronetics compare to InMode?

InMode (NASDAQ:INMD) and Neuronetics (NASDAQ:STIM) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, institutional ownership, earnings, media sentiment, valuation, risk and analyst recommendations.

68.0% of InMode shares are held by institutional investors. Comparatively, 53.6% of Neuronetics shares are held by institutional investors. 6.9% of InMode shares are held by insiders. Comparatively, 8.4% of Neuronetics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

InMode has a net margin of 20.69% compared to Neuronetics' net margin of -19.62%. InMode's return on equity of 11.99% beat Neuronetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InMode	20.69%	11.99%	10.60%
Neuronetics	-19.62%	-125.11%	-22.15%

InMode has a beta of 1.89, indicating that its share price is 89% more volatile than the broader market. Comparatively, Neuronetics has a beta of 1.03, indicating that its share price is 3% more volatile than the broader market.

InMode currently has a consensus price target of $16.00, suggesting a potential upside of 5.61%. Neuronetics has a consensus price target of $4.50, suggesting a potential upside of 36.36%. Given Neuronetics' stronger consensus rating and higher possible upside, analysts clearly believe Neuronetics is more favorable than InMode.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InMode	1 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Neuronetics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Neuronetics had 12 more articles in the media than InMode. MarketBeat recorded 15 mentions for Neuronetics and 3 mentions for InMode. InMode's average media sentiment score of 0.96 beat Neuronetics' score of 0.61 indicating that InMode is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
InMode	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Neuronetics	3 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

InMode has higher revenue and earnings than Neuronetics. Neuronetics is trading at a lower price-to-earnings ratio than InMode, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InMode	$370.49M	2.35	$93.83M	$1.23	12.32
Neuronetics	$149.16M	1.69	-$39M	-$0.54	N/A

Summary

InMode beats Neuronetics on 11 of the 16 factors compared between the two stocks.

How does Neuronetics compare to SiBone?

Neuronetics (NASDAQ:STIM) and SiBone (NASDAQ:SIBN) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, profitability, institutional ownership, earnings, risk, valuation, analyst recommendations and dividends.

In the previous week, Neuronetics had 11 more articles in the media than SiBone. MarketBeat recorded 15 mentions for Neuronetics and 4 mentions for SiBone. SiBone's average media sentiment score of 1.33 beat Neuronetics' score of 0.61 indicating that SiBone is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neuronetics	3 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
SiBone	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Neuronetics has a beta of 1.03, indicating that its share price is 3% more volatile than the broader market. Comparatively, SiBone has a beta of 0.66, indicating that its share price is 34% less volatile than the broader market.

SiBone has higher revenue and earnings than Neuronetics. SiBone is trading at a lower price-to-earnings ratio than Neuronetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neuronetics	$149.16M	1.69	-$39M	-$0.54	N/A
SiBone	$200.93M	4.18	-$18.90M	-$0.34	N/A

SiBone has a net margin of -6.85% compared to Neuronetics' net margin of -19.62%. SiBone's return on equity of -8.23% beat Neuronetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neuronetics	-19.62%	-125.11%	-22.15%
SiBone	-6.85%	-8.23%	-6.07%

Neuronetics presently has a consensus target price of $4.50, suggesting a potential upside of 36.36%. SiBone has a consensus target price of $24.17, suggesting a potential upside of 27.66%. Given Neuronetics' higher probable upside, analysts clearly believe Neuronetics is more favorable than SiBone.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neuronetics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
SiBone	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

53.6% of Neuronetics shares are held by institutional investors. Comparatively, 98.1% of SiBone shares are held by institutional investors. 8.4% of Neuronetics shares are held by company insiders. Comparatively, 4.0% of SiBone shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

SiBone beats Neuronetics on 11 of the 16 factors compared between the two stocks.

How does Neuronetics compare to Beta Bionics?

Beta Bionics (NASDAQ:BBNX) and Neuronetics (NASDAQ:STIM) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, risk, dividends, earnings, institutional ownership, analyst recommendations, valuation and media sentiment.

Beta Bionics has a beta of 3.13, meaning that its share price is 213% more volatile than the broader market. Comparatively, Neuronetics has a beta of 1.03, meaning that its share price is 3% more volatile than the broader market.

In the previous week, Neuronetics had 13 more articles in the media than Beta Bionics. MarketBeat recorded 15 mentions for Neuronetics and 2 mentions for Beta Bionics. Beta Bionics' average media sentiment score of 0.99 beat Neuronetics' score of 0.61 indicating that Beta Bionics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Beta Bionics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Neuronetics	3 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Beta Bionics presently has a consensus target price of $20.10, indicating a potential upside of 14.40%. Neuronetics has a consensus target price of $4.50, indicating a potential upside of 36.36%. Given Neuronetics' higher probable upside, analysts clearly believe Neuronetics is more favorable than Beta Bionics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beta Bionics	1 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.55
Neuronetics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

53.6% of Neuronetics shares are held by institutional investors. 5.3% of Beta Bionics shares are held by insiders. Comparatively, 8.4% of Neuronetics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Neuronetics has higher revenue and earnings than Beta Bionics. Beta Bionics is trading at a lower price-to-earnings ratio than Neuronetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beta Bionics	$100.25M	7.89	-$73.20M	-$1.65	N/A
Neuronetics	$149.16M	1.69	-$39M	-$0.54	N/A

Neuronetics has a net margin of -19.62% compared to Beta Bionics' net margin of -61.31%. Beta Bionics' return on equity of -26.30% beat Neuronetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Beta Bionics	-61.31%	-26.30%	-23.25%
Neuronetics	-19.62%	-125.11%	-22.15%

Summary

Neuronetics beats Beta Bionics on 10 of the 16 factors compared between the two stocks.

Get Neuronetics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding STIM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

STIM vs. The Competition

Export

Metric	Neuronetics	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$230.88M	$5.95B	$7.06B	$13.10B
Dividend Yield	N/A	1.76%	2.57%	10.45%
P/E Ratio	-7.50	21.85	211.09	21.74
Price / Sales	1.69	63.14	602.98	92.99
Price / Cash	N/A	33.92	70.48	50.90
Price / Book	11.79	6.10	12.91	6.24
Net Income	-$39M	$148.67M	$3.45B	$347.60M
7 Day Performance	38.66%	1.84%	1.12%	1.07%
1 Month Performance	86.44%	4.56%	1.79%	1.03%
1 Year Performance	-7.30%	8.67%	67.69%	20.77%

Neuronetics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
STIM Neuronetics	4.053 of 5 stars	$3.30 +8.9%	$4.50 +36.4%	-21.7%	$230.88M	$149.16M	N/A	180	Earnings Report Analyst Forecast
CBLL CeriBell	1.0764 of 5 stars	$23.24 0.0%	$22.00 -5.3%	+95.2%	$890.95M	$101.96M	N/A	N/A	Earnings Report Analyst Forecast Insider Trade
AVR Anteris Technologies Global	2.8612 of 5 stars	$9.07 +1.5%	$16.00 +76.5%	+120.0%	$883.57M	$1.91M	N/A	138	Earnings Report Analyst Forecast Insider Trade
INMD InMode	2.0283 of 5 stars	$15.17 -0.2%	$16.00 +5.5%	+3.8%	$871.68M	$370.49M	12.33	480
SIBN SiBone	3.3752 of 5 stars	$18.98 +0.2%	$24.17 +27.3%	+20.7%	$842.43M	$200.93M	N/A	350

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:STIM) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Neuronetics (STIM) Competitors

STIM vs. CBLL, AVR, INMD, SIBN, and BBNX

How does Neuronetics compare to CeriBell?

Summary

How does Neuronetics compare to Anteris Technologies Global?

Summary

How does Neuronetics compare to InMode?

Summary

How does Neuronetics compare to SiBone?

Summary

How does Neuronetics compare to Beta Bionics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

STIM vs. The Competition

Neuronetics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Neuronetics (STIM) Competitors

STIM vs. CBLL, AVR, INMD, SIBN, and BBNX

How does Neuronetics compare to CeriBell?

Is STIM or CBLL more profitable?

Do analysts prefer STIM or CBLL?

Does the media favor STIM or CBLL?

Do institutionals & insiders believe in STIM or CBLL?

Which has more risk and volatility, STIM or CBLL?

Which has better earnings & valuation, STIM or CBLL?

Summary

How does Neuronetics compare to Anteris Technologies Global?

Is STIM or AVR more profitable?

Do insiders and institutionals hold more shares of STIM or AVR?

Which has more volatility & risk, STIM or AVR?

Which has preferable earnings & valuation, STIM or AVR?

Does the media favor STIM or AVR?

Do analysts prefer STIM or AVR?

Summary

How does Neuronetics compare to InMode?

Do institutionals & insiders have more ownership in INMD or STIM?

Is INMD or STIM more profitable?

Which has more risk and volatility, INMD or STIM?

Do analysts prefer INMD or STIM?

Does the media prefer INMD or STIM?

Which has higher earnings & valuation, INMD or STIM?

Summary

How does Neuronetics compare to SiBone?

Does the media prefer STIM or SIBN?

Which has more risk & volatility, STIM or SIBN?

Which has preferable valuation & earnings, STIM or SIBN?

Is STIM or SIBN more profitable?

Do analysts prefer STIM or SIBN?

Do institutionals and insiders have more ownership in STIM or SIBN?

Summary

How does Neuronetics compare to Beta Bionics?

Which has more volatility & risk, BBNX or STIM?

Does the media refer more to BBNX or STIM?

Do analysts rate BBNX or STIM?

Do institutionals & insiders believe in BBNX or STIM?

Which has preferable earnings and valuation, BBNX or STIM?

Is BBNX or STIM more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

STIM vs. The Competition

Neuronetics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools